Oncotarget

Research Papers:

Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons

Prashanth Gokare, Arunasalam Navaraj, Shengliang Zhang, Noboru Motoyama, Shen-Shu Sung and Niklas K. Finnberg _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29520-29530. https://doi.org/10.18632/oncotarget.8790

Metrics: PDF 685 views  |   HTML 1175 views  |   ?  


Abstract

Prashanth Gokare1,2, Arunasalam Navaraj2, Shengliang Zhang1,2, Noboru Motoyama3, Shen-Shu Sung4, Niklas K. Finnberg1,2

1Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

2Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA 17104, USA

3Institute of Longevity, Department of Cognitive Brain Sciences Research Institute, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan

4Department of Pharmacology, Penn State College of Medicine, Hershey, PA 17104, USA

Correspondence to:

Niklas K. Finnberg, e-mail: niklas_finnberg@hotmail.com

Keywords: Chk2, topoisomerase inhibitors, apoptosis, etoposide, myelosuppression

Received: September 29, 2015     Accepted: March 28, 2016     Published: April 18, 2016

ABSTRACT

The DNA damage response (DDR) gene cell cycle checkpoint kinase 2 (Chk2) triggers programmed cell death and lethal radiation-induced toxicity in mice in vivo. However, it is not well established to what extent targeting of Chk2 may protect from dose-limiting toxicities (DLT) inflicted by mainstay cancer chemotherapy. We screened different classes of chemotherapy in wild type and Chk2-deficient cells. Here we show that loss of Chk2 protect from cell death in vitro and lethal toxicity in vivo following treatment with topoisomerase II (TOP2)–inhibitors whereas no such protection was observed following treatment with topoisomerase I (TOP1) inhibitors. Furthermore, through combined in silico and functional screens of the Diversity Set II (NCI/NTP) chemical library we identified the carbanilide-derivative NSC105171, also known as ptu-23, as a novel Chk2 inhibitor (Chk2i). Indeed, NSC105171 can be administered safely to mice to countermeasure etoposide-induced toxicity. Incorporation of Chk2i into chemotherapy protocols employing TOP2-inhibitors may be an effective strategy to prevent DLT’s without interfering with treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8790